Renaissance Technologies LLC Has $468,000 Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Renaissance Technologies LLC lifted its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 70.2% during the 2nd quarter, Holdings Channel reports. The firm owned 80,000 shares of the company’s stock after purchasing an additional 33,000 shares during the quarter. Renaissance Technologies LLC’s holdings in TScan Therapeutics were worth $468,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of TCRX. Dimensional Fund Advisors LP bought a new position in TScan Therapeutics during the second quarter worth about $70,000. Brown Brothers Harriman & Co. acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $445,000. Cornercap Investment Counsel Inc. bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $134,000. American Century Companies Inc. increased its holdings in shares of TScan Therapeutics by 48.9% during the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock worth $278,000 after acquiring an additional 15,596 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in TScan Therapeutics in the 2nd quarter valued at $274,000. 82.83% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was purchased at an average cost of $5.53 per share, with a total value of $27,650.00. Following the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $221,200. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction on Monday, August 26th. The shares were purchased at an average price of $5.53 per share, with a total value of $27,650.00. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $221,200. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 15,000 shares of company stock valued at $82,550 over the last 90 days. 2.76% of the stock is owned by corporate insiders.

TScan Therapeutics Stock Down 4.6 %

TCRX stock opened at $5.35 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77. The business’s fifty day moving average price is $5.61 and its two-hundred day moving average price is $6.89. TScan Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $9.69. The stock has a market capitalization of $283.39 million, a price-to-earnings ratio of -4.18 and a beta of 0.77.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $1.55 million. On average, equities analysts anticipate that TScan Therapeutics, Inc. will post -1.36 earnings per share for the current year.

Analysts Set New Price Targets

TCRX has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Monday, August 12th. Finally, Wedbush reissued an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.